Albion News

Exco InTouch, the leading provider of digital patient engagement and data capture solutions for clinical research and healthcare providers, today celebrates its recognition on the Sunday Times Hiscox Tech Track 100 – which ranks Britain’s fastest growing private technology companies. Exco InTouch is the only pharmaceutical technology company to be recognized on the list and this achievement is built on the company’s rapid acceleration of turnover – sales have tripled over the last three years, highlighting the company’s strengthening position. Pharma is now embracing new technology platforms... read more
The award ceremony will be taking place on 11 November 2015 at The Brewery, 52 Chiswell Street, London, EC1Y 4SD. More information can be found at the Education investor website read more
DySIS Medical
DySIS Medical, Inc. and Unified Women's Clinical Research (UWCR), a subsidiary of Unified Physician Management in Boca Raton, FL, announced a significant, multi-center research partnership with the DySIS Advanced Cervical Imaging System – a next-generation colposcope with computer-aided cervical imaging tools that is used to assess women after an abnormal Pap smear. UWCR is a premier research organisation that provides excellent proficiency in gynecologic trial execution through its unique alliance of OB/GYN women's health practices across the southeast. UWCR has conducted clinical trials on... read more
Exco InTouch
Albion has led a £3.2m investment round in Exco InTouch (“Exco”), a leading electronic Patient Reported Outcomes (“ePRO”) and patient engagement software business. Founder investor, Scottish Equity Partners (“SEP”), also participated in the round and remains the company’s largest shareholder. Founded in 2004 by its current CEO, Tim Davis, Exco provides mobile and digital services to pharmaceutical companies for the engagement and collection of information from patients in clinical trials and real-life settings (ePRO). This rapidly growing sector is being driven by the increasing need to... read more
Exco InTouch today announces that one million patients have now benefited from the company’s firmly established and industry leading platform. This significant number underlines the company’s established leadership position in the market and highlights the broad reach of Exco InTouch’s services. The company’s platform is highly scalable with the proven capability to support cross-border programs with large patient populations. As a consequence, at any one time hundreds of thousands of patients across multiple territories, time zones and languages benefit from Exco InTouch’s software and... read more
Exco InTouch today announced that it has been granted a US Patent corresponding to its mDNA® technology. mDNA® is an automated management tool that seamlessly identifies, distributes and manages patients and their mobile device interactivity in clinical and healthcare programs.   mDNA® provides study managers, sponsors and healthcare providers with effective control over the environment in which patients interact with mobile data capture services, thereby offering device management benefits for traditional, fully provisioned clinical trials. In addition, by managing each patients’... read more
Masters Speciality Pharma has announced the strengthening of its capabilities in Brazil through its acquisition of Masters Distribution Brazil. The new company, located in São Caetano do Sul, São Paulo, will become part of the Master Speciality Pharma Group, and contribute to the group’s future expansion and growth plans in Latin America. Since its incorporation eight years ago, Masters Pharmaceuticals Ltda, Brazil – the regional subsidiary of the Masters Speciality Pharma group – has focused on early-access programs through the named patient supply (NPS) of unlicensed medicines to patients... read more
– Study shows that ROCA® detects 86% of women with ovarian cancer before there are any symptoms; twice as many than the use of a single assessment of CA125.  – When ROCA® is used with an ultrasound scan as the follow up test, screening can rule out almost 100% of women who are cancer-free.  – Based on these impressive data, Abcodia prepares to launch ROCA® into the private market in 2015.  Abcodia, a specialist company engaged in the development of tests for the early detection of cancer, is to make ROCA® available as an innovative ovarian cancer screening test this year, on the back of new... read more
Masters Speciality Pharma is pleased to announce a partnership agreement with Speciality European Pharma (SEP) for the exclusive distribution of Mitocin®/Mitem® (mitomycin) - 22 October 2014  Masters Speciality Pharma is pleased to announce a partnership agreement with Speciality European Pharma (SEP) for the exclusive distribution of Mitocin®/Mitem® (mitomycin) to the Caribbean, Egypt, Kuwait, Iran, Saudi Arabia, UAE, Kenya, Seychelles, Uganda, Zimbabwe, Chile, Denmark, Greece, Ireland, Norway and Sweden.  Masters has 30 years experience in the ethical and compliant supply of drugs to... read more
Chris Roche will succeed David Sibbald in the role of chief executive, David will become executive chairman. Roche joined Aridhia a year ago as chief commercial officer and is credited with bringing a more commercial focus to the business as it shifts from traditional licensing of software to a central cloud-based delivery model. The firm recently announced it was partnering fellow Scottish health technology pioneer Craneware to target the US market.   Roche, who prior to joining Aridhia worked for global IT company EMC for 14 years, said: “My focus is now to accelerate our own business model... read more

Pages